Human cyclin-dependent kinase (hPNQALRE)

Details Human cyclin-dependent kinase (hPNQALRE) Human cyclin-dependent kinase (hPNQALRE)

2007-06-07

2010-12-21

Fronda, Christian L (Department: 1652)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S114000, C435S194000, C435S252300, C435S320100, C536S023200

Reexamination Certificate

active

07855058

ABSTRACT:
A human gene encoding a novel cyclin-dependent kinase termed hPNQALRE and its expression products can be used to provide reagents and methods for detecting neoplasia. Compositions and methods for treating proliferative disorders and neoplasia are also provided.

REFERENCES:
patent: 5968800 (1999-10-01), Gerhold
patent: 7250256 (2007-07-01), Reinhard
patent: 7566559 (2009-07-01), Reinhard
patent: 2007/0011783 (2007-01-01), Liu et al.
patent: WO 96-28555 (1996-09-01), None
patent: WO 97-25345 (1997-07-01), None
patent: WO 98-35015 (1998-08-01), None
patent: WO9835015 (1998-08-01), None
patent: WO 98-40483 (1998-09-01), None
Accession AAV32932 (published Aug. 13, 1998).
Accession AAV32932 protein alignment SEQ ID No. 2 (published Aug. 13, 1998).
Alignment US Patent 5968800 to protein SEQ ID No. 2 (filed Feb. 5, 1998 and issued Oct. 19, 1999).
Alignment US Patent 5968800 to SEQ ID No. 1 (filed Feb. 5, 1998 and issued Oct. 19, 1999).
Alignment 20070011783-A1 to SEQ ID No. 1 (published Jan. 11, 2007).
Fu et al. (Nov. 2006). “Identification of Yin-Yang Regulators and a Phosphorylation Consensus for Male Germ Cell-Associated Kinase (MAK)-Related Kinase.” Molecular and Cellular Biology, 26(22):8639-8654.
Lehninger et al. (1993).Principles of Biochemistry. 2nd edition. Worth Publishers. New York, pp. 1006-1007.
Spandidos et al. (1993). “Prognostic Significance of Oncogenes and Tumor Suppressor Genes in Human Malignancy,” Stem Cells 11:194-198.
Accession No. AAW49083, created Dec. 7, 1998, located at <http://es/ScoreAccessWeb/GetItem.action?AppId=11774306&seqId=09323b6780856f58&ItemName=2008> visited on Jul. 20, 2008, in program Score Access Web. (2 pages).
Alignment of CDK10 of D2 (WO-98/35015 filed Feb. 6, 1998) to Seq ID No. 4 of EP Application No. 99967389.0 filed Dec. 16, 1999, 1 page.
Alignment of HCEDH81 of D3 (WO-98/40483 filed Mar. 12, 1998) to Seq ID No. 4 of EP Application No. 99967389.0 filed Dec. 16, 1999, 1 page.
Alignment of SEQ ID No. 3 of U.S. Appl. No. 09/464,065 filed Dec. 15, 1999 (Reinhard) to GenBank Accession No. AA065538 last updated Feb. 3, 1997 (“Alignment 2”), 2 pages.
Alignment of SEQ ID No. 3 of US Patent No. 5,968,800 filed Feb. 5, 1998 (Gerhold) to SEQ ID No. 2 of U.S. Appl. No. 11/774,306 filed Jul. 6, 2007 (Reinhard), 2 pages.
Alignment of SEQ ID No. 5 of U.S. Appl. No. 09/464,065 filed Dec. 15, 1999 (Reinhard) to GenBank Accession No. AA065538 last updated Feb. 3, 1997 (“Alignment 3”), 2 pages.
Alignment of SEQ ID No. 6 of U.S. Appl. No. 09/454,065 filed Dec. 15, 1999 (Reinhard) to GenBank Accession No. AA065538 last updated Feb. 3, 1997 (“Alignment 1”), 1 page.
Chica, R. A. et al. (2005). “Semi-Rational Approaches to Engineering Enzyme Activity: Combining the Benefits of Directed Evolution and Rational Design,”Current Opinion in Biotechnology16:378-384.
Ciardiello, F. et al. (May 2001). “Inhibition of Growth Factor Production and Angiogenesis in Human Cancer Cells by ZD1839 (Iressa), a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,”Clinical Cancer Research7:1459-1465.
EMBL Accession No. AI386000, last updated Jan. 29, 1999, located at <http://srs.ebi.ac.uk/srsbin/cgi-bin/wgetz?-page+EntryPage+-id+1YUGI1Z7BNm+-e+[EMBL:AI386000]+-vn+2>visited on Jan. 23, 2009. (2 pages).
EMBL Accession No. P50613, last updated Oct. 1, 1996, located at <http://www.uniprot.org/uniprot/P50613.txt> visited on Jan. 23, 2009. (6 pages).
International Search Report mailed Sep. 18, 2000, for PCT Application No. PCT/US99/30113 filed Dec. 16, 1999, 6 pages.
Koeffler, H. P. et al. (Sep. 1980). “Human Myeloid Leukemia Cell Lines: A Review,”Blood56(3):344-350.
Mackeigan, J. P. et al. (Jun. 2005). “Sensitized RNAi Screen of Human Kinases and Phosphatases Identifies New Regulators of Apoptosis and Chemoresistance,”Nature Cell Biology7(6):591-600, Supplementary Information pp. 1-4.
Partial European Search Report and Written Opinion mailed Dec. 22, 2008, for EP Application No. 08006175.7 filed Dec. 16, 1999, 14 pages.
Partial European Search Report mailed Aug. 28, 2008, for EP Application No. 08006175.7 filed Dec. 16, 1999, 9 pages.
U.S. Office Action mailed Jul. 25, 2008, for U.S. Appl. No. 11/774,306 filed Jul. 6, 2007, 10 pages.
Wohlbold, L. et al. (Mar. 1, 2006). “The Cyclin-Dependent Kinase (CDK) Family Member PNQALRE/CCRK Supports Cell Proligeration but has No Intrinsic CDK-Activating Kinase (CAK) Activity,”Cell Cycle5(5):546-554.
Leibiger et al.,Short-Term Regulation of Insulin Gene Transcription by Glucose, Proceedings of the Nat'l Academy of Sciences of USA, 95:9307-9312 (1998).
Lock et al.,Potentiation of Etoposide-Induced Apoptosis by Staurosporine in Human Tumor Cells is Associated with Events Downstream of DNA-Protein Complex Formation, Cancer Chemother. Pharmocol, 39:399-409 (1997).
Morgan,Cyclin-Dependent Kinases: Engines, Clocks, and Microprocessors, Annu. Rev. Cell Dev. Biol., 13:261-291 (1997).
Accession No. AA065538 (1996), Marra, et al., Mus musculus cDNA clone IMAGE:515877 5′ similar to TR:G758205 G758205 CDC2PA Gene.
Lew et al.,Regulatory Roles of Cyclin Dependent Kinase Phosphorylation in Cell Cycle Control, Curr. Opin. Cell Biol., 8:795-804 (1996).
Shuttleworth,The Regulation and Function of cdk7, Prog. Cell Cycle Res., 1:229-240 (1995).
Hopp et al.,A Computer Program for Predicting Protein Antigenic Determinants, Mol. Immunol., 20(4):483-489 (1983).
Sutcliffe et al.,Antibodies That React with Predetermined Sites on Proteins, Science, 219:660-666 (1983).
Hopp et al.,Prediction of Protein Antigenic Determinants from Amino Acid Sequences, Proc. Nat'l. Acad. Sci. USA, 78(6) 3824-3828 (1981).
Whisstock et al, Q Rev Biophys. 36(3):307-40 (Aug. 2003).
Molina et al., Tumour Biol. 26(6):281-293 (Oct. 2005).
Database Biosis Biosciences Information Service, Philadelphia, PA, US: Oya M. et al.,Expression of G1fwdarwS transition regulatory molecules in human urothelial cancer, pp. 1-2, (Jul. 1998).
Meikrantz W. et al.,Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases, J. Biol. Chem., vol. 271, No. 17 pp. 10205-10209 (1996).
Liu, Y. et al.,p42, a novel cyclin-dependent kinase-activating kinase in mammalian cellsJ. Biol. Chem. vol. 279, No. 6, pp. 4507-4514 (2004).
U.S. Appl. No. 09/464,065, filed Dec. 15, 1999 for Reinhard.
Marra, M. et al. (Jan. 29, 1999). “ml54h11.y1 Stratagene mouse testis (#937308) Mus musculus cDNA clone IMAGE:515877 5′ similar to SW:KC47—ORYSA P29620 CDC2+/CDC28-Related Protein Kinase R2 ; mRNA sequence,” EMBL Database accession No. AI386000.
Pines, J. (1995). “Cyclins and cyclin-dependent kinases: a biochemical view,” Biochem. J. 308:697-711.
European Office Action mailed Mar. 19, 2010, for EP Application No. 08006175.7 filed Jul. 25, 2008, 3 pages.

Affiliated with

Also associated with

Rating

Human cyclin-dependent kinase (hPNQALRE) does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human cyclin-dependent kinase (hPNQALRE), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human cyclin-dependent kinase (hPNQALRE) will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4154048